The Food and Drug Administration recently approved AstraZeneca's (NYSE:AZN) Epanova, adding it to the growing list of omega-3 fish oil drugs that includes GlaxoSmithKline's (NYSE:GSK) Lovaza and Amarin's (NASDAQ:AMRN) Vascepa.
In the following video, senior biotech specialist Brian Orelli and health-care analyst David Williamson discus the market dynamics for fish oil drugs, which has Lovaza dominating the market even though Vascepa is arguably a better drug.
We'll have to see whether AstraZeneca can use its marketing muscle to succeed where Amarin has failed. Epanova has some advantages because it can be taken just once a day and doesn't have to be taken with food, but it's debatable whether thosae are big enough to get patients to switch.
Brian Orelli and The Motley Fool have no position in any stocks mentioned. David Williamson owns shares of Amarin. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.